European urology最新文献_第8页

Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer 建立反映患者获益的适当中间终点的挑战与机遇：非转移性前列腺癌研究与临床应用路线图。

IF 25.3 1区医学

European urology Pub Date : 2024-08-01 DOI: 10.1016/j.eururo.2024.04.024

引用次数: 0

Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial Cabozantinib联合Nivolumab治疗非透明细胞肾细胞癌患者：2期试验的最新结果。

IF 25.3 1区医学

European urology Pub Date : 2024-08-01 DOI: 10.1016/j.eururo.2024.04.025

{"title":"Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial","authors":"","doi":"10.1016/j.eururo.2024.04.025","DOIUrl":"10.1016/j.eururo.2024.04.025","url":null,"abstract":"<div><p><span>Treatment options are limited for patients with non–clear cell renal cell carcinoma (nccRCC). Patients with nccRCC experienced a favorable objective response rate (ORR) in a phase 2 trial of cabozantinib plus </span>nivolumab. We now report updated efficacy and safety results at median follow-up of 34 mo for patients with papillary, unclassified, or translocation-associated RCC. Cabozantinib and nivolumab were administered at standard doses to patients with metastatic nccRCC that had progressed on zero or one line of systemic therapy. The primary endpoint was the ORR according to Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse events. Forty patients were treated. At median follow-up of 34 mo for survivors, the ORR was 48% (95% confidence interval [CI] 31.5–63.9%). Median PFS was 13 mo (95% CI 7–16); the 12-mo and 24-mo PFS rates were 51% (95% CI 34–65%) and 23% (95% CI 11–37%), respectively. Median OS was 28 mo (95% CI 23–43); the 18-mo and 36-mo OS rates were 70% (95% CI 53–82%) and 44% (95% CI 28–60%), respectively. No new safety signals were seen with cabozantinib and nivolumab. This extended follow-up analysis demonstrates promising efficacy, and highlights the potential for sustained responses with cabozantinib plus nivolumab in patients with metastatic nccRCC.</p></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":null,"pages":null},"PeriodicalIF":25.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141089621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer 针对寡转移性前列腺癌的全身和肿瘤导向疗法：新寡转移性前列腺癌的 SOLAR 2 期试验。

IF 25.3 1区医学

European urology Pub Date : 2024-08-01 DOI: 10.1016/j.eururo.2024.02.008

引用次数: 0

Re: Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer 关于在阉割耐药前列腺癌中靶向抑制 CYP11A1。

IF 25.3 1区医学

European urology Pub Date : 2024-08-01 DOI: 10.1016/j.eururo.2024.03.030

引用次数: 0

Re: Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer (TROG 15.03 FASTRACK II): A Non-randomised Phase 2 Trial 关于立体定向消融体放射治疗原发性肾癌（TROG 15.03 FASTRACK II）：非随机 2 期试验。

IF 25.3 1区医学

European urology Pub Date : 2024-08-01 DOI: 10.1016/j.eururo.2024.04.003